304 related articles for article (PubMed ID: 10598301)
1. [Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine].
Dardennes R; Lafuma A; Watkins S
Encephale; 1999; 25(5):391-400. PubMed ID: 10598301
[TBL] [Abstract][Full Text] [Related]
2. [Prophylactic long-term therapy of affective disorders with lithium, valproic acid and carbamazepine--effectiveness and cost-effectiveness].
Roick C; Ahrens B; Becker T
Psychiatr Prax; 2001 Jul; 28 Suppl 1():S32-40. PubMed ID: 11533905
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial.
Revicki DA; Hirschfeld RM; Ahearn EP; Weisler RH; Palmer C; Keck PE
J Affect Disord; 2005 Jun; 86(2-3):183-93. PubMed ID: 15935238
[TBL] [Abstract][Full Text] [Related]
4. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
5. Health-economic implications of the onset of action of antimanic agents.
Keck PE; McElroy SL; Bennett JA
J Clin Psychiatry; 1996; 57 Suppl 13():13-8; discussion 19-22. PubMed ID: 8970501
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic and health outcome comparison of lithium and divalproex in a VA geriatric nursing home population: influence of drug-related morbidity on total cost of treatment.
Conney J; Kaston B
Am J Manag Care; 1999 Feb; 5(2):197-204. PubMed ID: 10346515
[TBL] [Abstract][Full Text] [Related]
7. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay.
Frye MA; Altshuler LL; Szuba MP; Finch NN; Mintz J
J Clin Psychiatry; 1996 Jan; 57(1):17-21. PubMed ID: 8543542
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up.
Baethge C; Gruschka P; Berghöfer A; Bauer M; Müller-Oerlinghausen B; Bschor T; Smolka MN
J Affect Disord; 2004 Apr; 79(1-3):43-50. PubMed ID: 15023479
[TBL] [Abstract][Full Text] [Related]
9. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients.
Placidi GF; Lenzi A; Lazzerini F; Cassano GB; Akiskal HS
J Clin Psychiatry; 1986 Oct; 47(10):490-4. PubMed ID: 3093468
[TBL] [Abstract][Full Text] [Related]
10. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders--a retrospective study.
Juckel G; Mavrogiorgou P; Bredemeier S; Gallinat J; Frodl T; Schulz C; Möller HJ; Hegerl U
Pharmacopsychiatry; 2004 Mar; 37(2):46-51. PubMed ID: 15048610
[TBL] [Abstract][Full Text] [Related]
11. Carbamazepine as adjunct or alternative to lithium in the prophylaxis of recurrent affective disorders.
Fritze J; Beneke M; Lanczik M; Schneider B; Walden J
Pharmacopsychiatry; 1994 Sep; 27(5):181-5. PubMed ID: 7838887
[TBL] [Abstract][Full Text] [Related]
12. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
[TBL] [Abstract][Full Text] [Related]
13. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of lithium in the prophylaxis of affective disorders].
Ezquiaga E; García-López A; Nieves P; Rodríguez-Salvanés F
Actas Esp Psiquiatr; 2000; 28(3):156-60. PubMed ID: 11000697
[TBL] [Abstract][Full Text] [Related]
15. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: double-blind, placebo-controlled studies.
Zhang ZJ; Kang WH; Li Q; Tan QR
J Psychiatr Res; 2007 Nov; 41(10):828-36. PubMed ID: 17010995
[TBL] [Abstract][Full Text] [Related]
16. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder.
Greil W; Kleindienst N
Int Clin Psychopharmacol; 1999 Sep; 14(5):277-81. PubMed ID: 10529070
[TBL] [Abstract][Full Text] [Related]
17. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
18. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
19. Predictors of compliance with lithium and carbamazepine regimens in the long-term treatment of recurrent mood and related psychotic disorders.
Lenzi A; Lazzerini F; Placidi GF; Cassano GB; Akiskal HS
Pharmacopsychiatry; 1989 Jan; 22(1):34-7. PubMed ID: 2652160
[TBL] [Abstract][Full Text] [Related]
20. [Investigation on the therapeutic effect of carbamazepine on the mood disorders in Japan].
Okuma T
Seishin Shinkeigaku Zasshi; 2005; 107(5):415-22. PubMed ID: 15981617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
